Stock Price
76.66
Daily Change
-3.03 -3.80%
Monthly
12.77%
Yearly
387.97%
Q2 Forecast
71.19

Arrowhead Research reported $-0.93 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q2 Mar/2026 -0.93 -1.04 2.75 May/07
FY2026Q1 Dec/2025 0.22 0.04 -1.39 Feb/05
FY2025Q4 Sep/2025 -0.11 -0.23 -1.36 Nov/25
FY2025Q3 Jun/2025 -1.26 -0.86 -1.38 Aug/07
FY2025Q2 Mar/2025 2.75 -0.11 -1.02 May/12




Eps Change Date
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
Anika Therapeutics USD 0.13 0.35 Dec/2025
Arrowhead Research USD -0.93 1.15 Mar/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Incyte USD 1.81 0.01 Mar/2026
Ionis Pharmaceuticals USD -0.56 0.85 Mar/2026
Ligand Pharmaceuticals USD 1.63 0.39 Mar/2026
Merck USD -1.28 3.32 Mar/2026
Moderna USD -3.4 1.29 Mar/2026
Nektar Therapeutics USD -1.35 1.17 Dec/2025
Novartis USD 1.99 0.04 Mar/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
TG Therapeutics USD 0.12 0.02 Mar/2026
Ultragenyx Pharmaceutical USD -1.84 0.55 Mar/2026
Vertex Pharmaceuticals USD 4.47 0.56 Mar/2026
Xencor USD -1.71 1.62 Mar/2026